Drug · CHEMBL1014
CANDESARTAN CILEXETIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CANDESARTAN CILEXETIL. Drugs and targets, record CHEMBL1014. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1014
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 7 of its 10 diseases, from DailyMed, FDA and PMDA
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | Type-1 angiotensin II receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/185 |
Source ChEMBL
Diseases10
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
Source Open Targets
Trials54
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00434967 | Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo | Phase 3 | 2,207 | 2009-06-17 | candesartan cilexetil | Its name | ClinicalTrials.gov |
| NCT01788358 | Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension | Phase 3 | 508 | 2015-08-17 | candesartan cilexetil | Its name | ClinicalTrials.gov |
| NCT00621153 | Candesartan Effect in Second Stage Arterial Hypertension | Phase 4 | 214 | 2010-03-23 | candesartan cilexetil | Its name | ClinicalTrials.gov |
| NCT00573430 | ARIA (Atacand Renoprotection In NephropAthy Pt.) | Phase 4 | 128 | 2011-07-19 | candesartan cilexetil | Its name | ClinicalTrials.gov |
| NCT00244621 | Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age | Phase 3 | 95 | 2009-09-15 | candesartan cilexetil | Its name | ClinicalTrials.gov |
| NCT01052272 | Impact of Diabetes on Left Ventricular Remodeling | Phase 2/3 | 72 | 2012-12-17 | candesartan cilexetil | Its name | ClinicalTrials.gov |
| NCT00690612 | Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics) | Phase 3 | 35 | 2011-06-29 | candesartan cilexetil | Its name | ClinicalTrials.gov |
| NCT01976572 | Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects | Phase 1 | 18 | 2015-10-30 | candesartan cilexetil | Its name | ClinicalTrials.gov |
| NCT02211638 | Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」 | 18,113 | 2018-11-05 | candesartan cilexetil | Its name | ClinicalTrials.gov | |
| NCT02166697 | Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome" | 14,151 | 2016-07-11 | candesartan cilexetil | Its name | ClinicalTrials.gov |
1 to 10 of 54
See all 54 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials17
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 26829251 | RESULT | 1 | PubMed |
| 16537662 | RESULT | 1 | PubMed |
| 40892621 | DERIVED | 1 | PubMed |
| 38682786 | DERIVED | 1 | PubMed |
| 37466151 | DERIVED | 1 | PubMed |
| 33073631 | DERIVED | 1 | PubMed |
| 29876358 | DERIVED | 1 | PubMed |
| 28734660 | DERIVED | 1 | PubMed |
| 27161546 | DERIVED | 1 | PubMed |
| 25627429 | DERIVED | 1 | PubMed |
1 to 10 of 17
See all 17 papers from its trialsTests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1014
GET https://conductscience.org/api/drugs/v1/CHEMBL1014/trials?page=2